Connect Biopharma Holdings Limited · NASDAQ:CNTB

Connect Biopharma — Technical Presentation (September 2026)

15 slides from Connect Biopharma's technical presentation, Sep 30, 2026

  1. Slide 1: Rademikibart Add-on Treatment of an Acute COPD Exacerbation Preliminary Results (Seabreeze STAT COPD)

    CBP-201-207 Rademikibart Add-on Treatment of an Acute COPD Exacerbation Preliminary Results (Seabreeze STAT COPD) Exhibit 99.2

  2. Slide 2: Forward-looking statements

    2 This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the “Act”). Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events,

  3. Slide 3: Phase 2 Clinical Trial of Rademikibart for Treatment of Acute COPD Exacerbations

    3 Phase 2 Clinical Trial of Rademikibart for Treatment of Acute COPD Exacerbations Abbreviations: COPD = Chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second; PRO =patient-reported outcome; SC = subcutaneous; SOC = standard of care: SOC + Placebo SC (n=81) Assessment of

  4. Slide 4: Phase 2 Seabreeze STAT COPD Study Participant Disposition

    4Phase 2 Seabreeze STAT COPD Study Participant Disposition S C R E E N E D 325 S C R E E N F A I L E D 166 Reasons (participants may have >1) Did Not Meet Eligibility Criteria 99 (59.6%) No Exacerbation During Screening 63 (38.0%) Physician Decision 2 (1.2%) Participant Withdrew Consent 9 (5.4%) Los

  5. Slide 5: Phase 2 Seabreeze STAT COPD Demographics and Baseline Characteristics

    5 Placebo (N=81) n (%) Rademikibart (N=78) n (%) Age (years): Mean (SD); Min, Max 66.6 (7.94); 45, 80 64.9 (9.26); 40, 80 Sex: Male Female 52 (64.2%) 29 (35.8%) 45 (57.7%) 33 (42.3%) Ethnicity: Not Hispanic 68 (84.0%) 70 (89.7%) Race: White Black Pacific Islander 81 (100.0%) 0 0 74 (94.9%) 4 (5.1%)

  6. Slide 6: 81% Reduction in TxF with Rademikibart & 100% Reduction in Hospital/ED Returns

    6 81% Reduction in TxF with Rademikibart & 100% Reduction in Hospital/ED Returns in One Month after Randomization Placebo (n=81) Rademikibart (n=78) P-value (Preliminary) Treatment Failure Rate* 11 (13.6%) 2 (2.6%) 81% reduction p=0.0122 Death 0 0 Admission or readmission to hospital for COPD 4 (4.9

  7. Slide 7: Time to Treatment Failure

    7Time to Treatment Failure 0.60 0.80 1.00 0 7 14 21 28 Pr ob ab ili ty o f n ot e xp er ie nc in g a tr ea tm en t f ai lu re Days following IP administration Time to Treatment Failure Through Week 4 Visit* Placebo (n=81) Rademikibart (n=78) Censored (placebo) Censored (rademikibart) * Per protocol,

  8. Slide 8: Rate of New Exacerbations Also Lower in Study

    8Rate of New Exacerbations Also Lower in Study 207 Placebo (n=81) Rademikibart (n=78) P-value Rate of new exacerbations through Week 4 visit 7 (8.6%) 1 (1.3%) 85% reduction 0.0301 Note: Study 207 was powered based on Treatment Failure primary endpoint and not secondary endpoints. Rate of new COPD ex

  9. Slide 9: Key Secondary Endpoint – Post-Bronchodilator FEV1 Not Significant

    9 Key Secondary Endpoint – Post-Bronchodilator FEV1 on Day 7 Not Significant Preliminary Topline Results 0 20 40 60 80 100 120 140 160 C ha ng e fro m B as el in e in P os t-B D F EV 1 (m L) Change from Baseline in Post-Bronchodilator FEV1 * Rademikibart (n=78) Placebo (n=81) Δ0 mL p - NS Δ70 mL p=0

  10. Slide 10: Significant Decrease in Rescue Inhaler Use Starting Week 2

    10 Significant Decrease in Rescue Inhaler Use Starting Week 2 Preliminary Topline Results 0 0.05 0.1 0.15 0.2 0.25 0.3 Av er ag e D ai ly P uf fs o f R es cu e In ha le r Average Daily Puffs of Rescue Inhaler Rademikibart (n=78) Placebo (n = 81) p=0.016 p = 0.245 *p-values comparing rademikibart to

  11. Slide 11: EXACT PRO Total Score and Individual Symptom Scores Lower at All Timepoints

    11EXACT PRO Total Score and Individual Symptom Scores Lower at All Timepoints in Study 207 EXACT PRO Total Score Placebo (n=81) Rademikibart (n=78) P-value Week 1 Mean (SD) LSMD 38.01 (10.885) 34.88 (11.428) -4.18 (1.947) 0.0334 Week 2 Mean (SD) LSMD 33.84 (12.318) 29.82 (12.859) -5.39 (2.282) 0.019

  12. Slide 12: Phase 2 Seabreeze STAT COPD Study Adverse Event Summary

    12 Placebo (N=81) n (%) Rademikibart (N=78) n (%) Any TEAE 21 (25.9%) 11 (14.1%) SAE 7 (8.6%) 2 (2.6%) TEAEs possibly related to IP 1 (1.2%) 0 TEAEs ≥Grade 3 7 (8.6%) 1 (1.3%) AESIs 0 0 TEAEs of DILI 0 0 TEAEs leading to IP discontinuation 0 0 TEAEs leading to trial withdrawal 0 0 Phase 2 Seabreeze

  13. Slide 13: Phase 2 Seabreeze STAT COPD Study Adverse Event Details

    13 Placebo (N=81) Rademikibart (N=78) COPD (n=6; exacerbation) Atrial fibrillation* (n=1) Pneumonia (n=1)  SAE  Grade ≥3 TEAE Death of unknown cause** (n=1; Day 37)  SAE  Grade ≥3 TEAE Injection site reaction (n=1)  Possibly related TEAE COPD (n=1; exacerbation, Day 39)  SAE COPD (n=6; exacerb

  14. Slide 14: 2025 US National Claims Data: Distribution of Emergency Visits for COPD with Costs

    2025 US National Claims Data Patients Aged 40 and Over Distribution of Emergency Visits for COPD with Costs Acute COPD exacerbation 3,457,573 ER visits/yr Not type 2–high · 1,863,632 · 53.9% not carried forward Type 2–high 1,593,941 46.1% 50% of the 90-day downstream spend lands in the first month.

  15. Slide 15: Study 207 Topline Results - Conclusions

    15 • Through 4 weeks rademikibart significantly reduced: • Treatment Failure (TxF) by 81% (p=0.0122) • New moderate to severe exacerbations by 85% (p=0.030) • ED and hospital admissions for exacerbations by 100% (0.014) • Clinically meaningful increase in post-bronchodilator FEV1 of 70 mL compared t

Connect Biopharma Holdings — Technical Presentation (September 2026) on 6ix